Abstract
Kakkalide, a compound obtained from a traditional Chinese medicine Puerariae flos, has been shown significant anti-ischemia activity in animal experiments recently. However, the solubility of the compound need to be enhanced with hydroxypropyl-β-cyclodextrin, which is a strong controversial solution adjuvant via intravenous administration. Methylamine irisolidone is a structurally modified kakkalide with good solubility in the water. In this study, the effect of this new compound on acute myocardial ischemia in dogs was investigated. The results showed that methylamine irisolidone (80 mg/kg, i.v) could reduce the myocardial infarct areas in dogs with myocardial infarction. The serum lactate dehydrogenase (LDH) activity and MB isoenzyme of creatine kinase (CK-MB) were suppressed by methylamine irisolidone after 240 min of administration. These results suggested that methylamine irisolidone exerts the protective effects on myocardial ischemia injury, which may be due to its function of inhibiting LDH and CK-MB releasing, stabilizing myocardial cell membrane and improving myocardial microcirculation and metabolism.
Recommended Citation
Mu, Y.-L.; Xie, Y.-Y.; Wang, F.-W.; Zhong, Y.; Li, J.; Hu, Z.-L.; Wang, Y.-S.; and Zhang, X.-M.
(2009)
"Protective effect of methylamine irisolidone, a novel compound, on acute myocardial ischemia in anesthetized dogs,"
Journal of Food and Drug Analysis: Vol. 17
:
Iss.
1
, Article 3.
Available at: https://doi.org/10.38212/2224-6614.2302
